Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Context.—There have been major advances in the understanding of melanoma since the
last revision of the World Health Organization (WHO) classification in 2006. Objective.—To …

Recent breakthroughs in tumor immunotherapy such as immune checkpoint blockade (ICB)
antibodies, have demonstrated the capacity of the immune system to fight cancer in a …

The incidence of primary cutaneous melanoma continues to increase each year. Melanoma
accounts for the majority of skin cancer–related deaths, but treatment is usually curative …

The highly complex and heterogenous ecosystem of a tumour not only contains malignant
cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts …

Assessment of the immune response to tumors is growing in importance as the prognostic
implications of this response are increasingly recognized, and as immunotherapies are …

Melanoma is a skin cancer caused by a malignancy of melanocytes. Incidence of melanoma
is rapidly increasing worldwide, which results in public health problems. Primary …

Cutaneous melanoma is a highly immunogenic malignancy that is surgically curable at early
stages but life-threatening when metastatic. Here we integrate high-plex imaging, 3D high …

Tumours grow within an intricate network of epithelial cells, vascular and lymphatic vessels,
cytokines and chemokines, and infiltrating immune cells. Different types of infiltrating …